Recent studies demonstrate that oxidative inactivation of tetrahydrobiopterin (H4B) may cause uncoupling of endothelial nitric oxide synthase (eNOS) to produce superoxide (O 2 •؊ ). H4B was found recyclable from its oxidized form by dihydrofolate reductase (DHFR) in several cell types. Functionality of the endothelial DHFR, however, remains completely unknown. Here we present findings that specific inhibition of endothelial DHFR by RNA interference markedly reduced endothelial H4B and nitric oxide (NO • ) bioavailability. Furthermore, angiotensin II (100 nmol͞liter for 24 h) caused a H4B deficiency that was mediated by H2O2-dependent downregulation of DHFR. This response was associated with a significant increase in endothelial O 2
production at 24 h that predominantly depended on uncoupled eNOS. Overexpression of DHFR restored NO • production and diminished eNOS production of O 2 •؊ in angiotensin II-stimulated cells. In conclusion, these data represent evidence that DHFR is critical for H4B and NO • bioavailability in the endothelium. Endothelial NAD(P)H oxidase-derived H2O2 down-regulates DHFR expression in response to angiotensin II, resulting in H4B deficiency and uncoupling of eNOS. This signaling cascade may represent a universal mechanism underlying eNOS dysfunction under pathophysiological conditions associated with oxidant stress.
hydrogen peroxide ͉ tetrahydrobiopterin ͉ superoxide I t has become apparent over the past decade that excessive production of reactive oxygen species (ROS) contributes to cardiovascular pathogenesis (1) (2) (3) . Indeed, scavenging ROS restored endothelial function in animal models of hypertension and atherosclerosis (3) . Antioxidant trials however produced mixed results in patients regarding disease prevention or regression, possibly because of incomplete understanding of antioxidant chemistry in vivo, inappropriate criteria for patient recruitment (4, 5) , or nonspecific nature of most antioxidants. The latter is an important issue to consider because it has remained unclear whether one particular ROS is dominantly important in pathological signaling (1) . Additionally, mixed results may suggest that some downstream pathological events are not readily reversible by removal of ROS. Recent studies demonstrate that endothelial nitric oxide synthase (eNOS) (and other isoforms of NOS) is capable of transforming into a prooxidant, O 2
•Ϫ -generating enzyme in vitro and in vivo (1, 3, (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . This phenomenon is now referred to as ''eNOS uncoupling.'' It is interesting to speculate that unsatisfactory outcomes of some antioxidant therapies are partially due to their ineffectiveness in restoring eNOS function in the vasculature or, in other words, ''recoupling'' of eNOS.
Although molecular mechanisms underlying eNOS uncoupling remain to be fully elucidated, a deficiency in eNOS cofactor tetrahydrobiopterin (H 4 B) appears to be a major cause (6, 8, (10) (11) (12) (13) (14) . The precise mechanisms as to how H 4 B became persistently deficient under pathological conditions, however, remain obscure. Dihydrofolate reductase (DHFR) catalyzes regeneration of H 4 B from its oxidized form, dihydropterin, in several cell types (16, 17) . Genes encoding DHFR have also been cloned. Functionality of the endothelial DHFR, however, remains completely unknown. Here we found that specific inhibition of endothelial DHFR through RNA interference (RNAi) led to a marked reduction in endothelial H 4 B and NO
• bioavailability. In hypertension-or diabetes-related atherosclerosis, angiotensin II is a major pathological player (5) . Many of the untoward effects of angiotensin II have been attributed to its ability to stimulate ROS production from vascular NAD(P)H oxidases (1, 2). Here we found that angiotensin II rapidly and transiently activated endothelial NAD(P)H oxidases to produce O 2
•Ϫ within 30 min, leading to H 2 O 2 -dependent down-regulation of DHFR, H 4 B deficiency, and a second phase O 2
•Ϫ production from uncoupled eNOS after 24 h. Overexpression of DHFR restored NO • production and abolished eNOS production of O 2
•Ϫ in angiotensin II-stimulated cells. These data characterize an essential role of endothelial DHFR in maintaining H 4 B and NO
• bioavailability in the endothelium. The observation that NAD(P)H oxidase-derived H 2 O 2 mediates angiotensin II uncoupling of eNOS via down-regulation of DHFR may have general applicability to other pathological conditions in which eNOS dysfunction occurs.
Human DHFR cDNA in pcDNA3.1 vector was a kind gift from Edward Chu and Ningwen Tai (Yale University, New Haven, CT). Aorta from mice deficient in angiotensin converting enzyme (ACE Ϫ/Ϫ ) were kindly provided by Kenneth E. Bernstein and Hong Xiao (Emory University, Atlanta). (18, 20) . In brief, endothelial cells cultured on Petri dishes were rinsed with modified Kreb's͞Hepes buffer and incubated with freshly prepared, NO
• -specific spin trap Fe 2ϩ (diethyldithiocarbamate) 2 colloid (0.5 mmol͞liter) for 60 min. Gently collected suspensions of cells were snap-frozen in liquid nitrogen and loaded into a finger Dewar for analysis with a Miniscope 200 ESR spectrophotometer (Magnettech, Berlin) at the following settings: biofield, 3267; field sweep, 100 G (1 G ϭ 0.1 mT); microwave frequency, 9.78 GHz; microwave power, 40 mW; modulation amplitude, 10 G; 4,096 points of resolution; and receiver gain, 900.
ESR Detection of Superoxide Radical. Gently collected endothelial cells were suspended in modified Kreb's͞HEPEs buffer containing deferoximine (25 mol͞liter, metal chelator). Approximately 1 ϫ 10 6 cells were mixed with 1 mmol͞liter O 2 •Ϫ -specific spin trap 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine in the presence or absence of 100 units͞ml polyethylene glycol (PEG)-conjugated O 2
•Ϫ dismutase (22) . The cell mixture loaded in glass capillaries was immediately analyzed for O 2
•Ϫ production kinetically for 10 min. The ESR settings were as follows: biofield, 3350; field sweep, 60 G; microwave frequency, 9.78 GHz; microwave power, 20 mW; modulation amplitude, 3 G; 4,096 points of resolution; receiver gain, 500; and kinetic time, 10 min. The O 2
•Ϫ signals at a 10 min time point and normalized by protein concentrations were compared among different experimental groups.
HPLC Determination of Endothelial H4B Content. Endothelial cells were lysed by using trichloroacetic acid containing 10 mmol͞liter DTT. Lysates were subjected to differential oxidation in acidic (0.2 M trichloroacetic acid) or alkalytic (0.1 M NaOH) solutions containing 2.5% I 2 ͞10% KI or 0.9% I 2 ͞1.8% KI. After centrifugation, 20 l of supernatant was injected into a HPLC system equipped with a 250-ϫ 4.6-mm C18 column (Alltech, Deerfield, IL) and a highly sensitive fluorescent detector (Schimadzu model RF-10Axl, Fisher). Excitation and emission wavelengths of 350 nm and 450 nm were used to detect fluorescent H 4 B and its oxidized species (15) . Because H 4 B is protected under acidic conditions and converted to pterin under alkalytic conditions, the difference in peak intensity reflects H 4 B content. The absolute H 4 B contents were calculated against a standard curve prepared by using purified H 4 B that went through identical extraction procedures and presented as pmol͞mg protein. •Ϫ levels among control, angiotensin II-or H 2 O 2 -stimulated cells, and cells pretreated with PEG-conjugated catalase (PEG-CAT) or Nnitro-L-arginine-methyl ester (L-NAME) was compared by using ANOVA, followed by Dunnett's post hoc test. Similarly, O 2
•Ϫ and NO
• productions in pcDNA3.1-DHFR transfected cells with or without angiotensin II stimulation were compared with the controls by using ANOVA. Differences in O 2
•Ϫ production in the presence or absence of L-NAME or NSC 23766 at different time points after angiotensin II stimulation was also analyzed with ANOVA. Statistical significance was set for P Ͻ 0.05.
Results
RNAi Silencing of DHFR Reduces Endothelial H4B and NO • Bioavailability. DHFR recycles H 4 B in several cell types (16, 17) . Its functionality within endothelium particularly regarding H 4 B and NO
• bioavailability, however, remains unclear. We therefore first examined the consequences of specific disruption of endothelial DHFR by using RNAi. As demonstrated by the fluorescent images in Fig. 1A , siRNAs were successfully transfected into Ϸ95% of the cells. DHFR-targeting siRNA markedly decreased DHFR protein expression by Ͼ90% (Fig. 1B) , consistent with the findings by Tai et al. (23) . Endothelial H 4 B content was 1.89 Ϯ 0.11 pmol͞mg protein in control siRNA-transfected cells and was significantly decreased to 1.26 Ϯ 0.11 pmol͞mg protein in cells transfected with DHFR siRNA (Fig. 1C) . Importantly, RNAi-induced specific disruption of DHFR was associated with a substantial decline in endothelial cell production of NO • (Fig. 2) . (Fig. 3 A  and B) . H 2 O 2 decreased the DHFR͞eNOS ratio from 1.6 Ϯ 0.28 to 0.6 Ϯ 0.10 in the controls (Fig. 3C) , implying that substantially less DHFR per se is available to supply recycled H 4 B to eNOS.
Angiotensin II Down-Regulation of DHFR Expression. Elevated angiotensin II levels have been observed in patients with atherosclerotic risk factors, including hypertension, diabetes, and renal dysfunction (2, 5) . Interestingly, angiotensin II stimulation (100 nmol͞liter for 24 h) of endothelial cells decreased DHFR expression by Ͼ50%, as reflected by representative Western blot and grouped data (Fig. 4 A and B) . Similar to H 2 O 2 , angiotensin II shifted DHFR͞eNOS ratio from 1.5 Ϯ 0.17 to 0.6 Ϯ 0.16 in the controls (Fig. 4C) . In ACE Ϫ/Ϫ mice, for which angiotensin II production was diminished, aortic expression of DHFR was more than doubled compared with wild-type controls (Fig. 4D) . Taken together, these data strongly suggest that angiotensin II down-regulates DHFR expression under physiological circumstances and that a pathological level of angiotensin II further reduces DHFR abundance. (Fig. 5A ). H 2 O 2 however increased biopterin content modestly by 30% (Fig. 5A) . These data seem consistent with the previous report that H 2 (Fig. 5B) . Importantly, scavenging of intracellular H 2 O 2 with a pretreatment of 100 units͞ml PEG-CAT for 1 h preserved H 4 B content (1.93 Ϯ 0.15 pmol͞mg protein) while having no effect on total biopterin, clearly impli- 
(B) Grouped densitometric data of DHFR expression (n ϭ 6). (C) Grouped data on DHFR͞eNOS ratio (n ϭ 6). (D)
Representative Western blot and grouped data on aortic DHFR expression from wild-type and ACE Ϫ/Ϫ mice (n ϭ 6). Data are presented at mean Ϯ SEM.
* , P Ͻ 0.05. (Fig. 5B) . In addition, PEG-CAT prevented angiotensin II down-regulation of DHFR (Fig. 5C ). Fig. 6 , angiotensin II (100 nmol͞liter for 24 h) induced a significant increase in endothelial O 2
•Ϫ production. This response was completely attenuated by the eNOS inhibitor L-NAME (100 mol͞liter) or PEG-CAT (100 units͞ml), strongly implying H 2 O 2 -dependent uncoupling of eNOS.
To directly examine the role of DHFR in angiotensin II uncoupling of eNOS, we transfected endothelial cells with mammalian expression vector containing human DHFR, pcDNA3.1-DHFR. Whereas angiotensin II (100 nmol͞liter for 24 h) consistently stimulated O 2
•Ϫ production in reagent-onlytransfected cells, it failed to evoke endothelial production of O 2
•Ϫ in DHFR-transfected cells (Fig. 7A) . DHFR overexpression also restored NO • production in angiotensin II-stimulated cells (Fig.  7B) . These data strongly suggest that DHFR availability is critical in maintaining the coupling state of eNOS.
Role of Endothelial NAD(P)H Oxidases. To examine whether a transient or continuous production of O 2
•Ϫ is required for H 2 O 2 -dependent eNOS uncoupling and to determine the enzymatic source responsible for the initial O 2
•Ϫ production, cells were exposed to angiotensin II for 30 min, 6 h, or 24 h. As is evident in Fig. 8A , angiotensin II stimulated a rapid production of O 2
•Ϫ at 30 min, which was unaffected by 100 mol͞liter L-NAME but abolished by 50 mol͞liter Rac1 inhibitor NSC 23766, indicating a role of endothelial NAD(P)H oxidases. This initial production of O 2 •Ϫ was transient because it diminished at 6 h (Fig. 8A) . Twenty-four hours after angiotensin II, there was a potent second peak in O 2
•Ϫ production, which was completely and consistently attenuated by L-NAME and unaffected by NSC 23766, implicating that uncoupled eNOS was predominantly responsible for O 2
•Ϫ production after prolonged exposure to angiotensin II (Fig. 8A) . Of note, DHFR expression did not change at 30 min, showed a slight downward trend at 6 h, but was markedly diminished at 24 h (Fig. 8B) . Take together, these data demonstrate that an initial and transient activation of endothelial NAD(P)H oxidases in response to angiotensin II lies upstream of H 2 O 2 -dependent down-regulation of DHFR and eNOS uncoupling. The overall findings of the study are summarized thematically in Fig. 9 .
Discussion
The present study elucidated that DHFR is critical for H 4 B and NO • bioavailability in the endothelium. Angiotensin II downregulates DHFR in a H 2 O 2 -dependent manner, and this response is involved in angiotensin II-induced H 4 B deficiency and eNOS uncoupling. The initiating source of H 2 O 2 appears to be the endothelial NAD(P)H oxidases, which lie upstream of uncoupled eNOS in response to angiotensin II. This cascade of signaling events, as illustrated in Fig. 9 , may represent a common mechanism underlying eNOS dysfunction under situations associated with oxidant stress. H 4 B belongs to a large pterin family. Pterins are 2-amino-4-oxo derivatives of pteridines, which, in turn, represent a large and structurally varied group of natural compounds involved in the biosynthetic pathways of cofactors and vitamins (25) . Although both oxidized and reduced pterins are detectable in physiological fluid and tissues, only H 4 B is biologically active (25) . The de novo synthesis of H 4 B involves the rate-limiting GTP-CH I, 6-pyruvoyl-H 4 B synthase and sepiapterin reductase (16, 17) . When H 4 B is oxidized to dihydropterin, it is recycled by DHFR in several cell types (16, 17) . Previous studies demonstrated that inhibition of GTP-CH I impaired endothelium-dependent relaxation (26) . Overexpression of GTP-CH I was found partially effective in improving endothelial function in diabetic (27) and hypertensive rodents (28) . However, functional regulation of the salvage enzyme DHFR, which could be more crucial in determining H 4 B and NO
• bioavailability under pathophysiological conditions associated with oxidant stress, remains obscure. Here we found that RNAi silencing of DHFR substantially reduced H 4 B and NO
• levels in cultured endothelial cells, implying an important role of DHFR in maintaining NO
• bioavailability under physiological conditions. Furthermore, endothelial DHFR expression was significantly down-regulated by pathological concentrations of angiotensin II. The ACE Ϫ/Ϫ mice had a doubling in aortic expression of DHFR compared with the wide-type controls. These data indicate that angiotensin II modulates DHFR under pathophysiological circumstances. Of caution, these observations do not necessarily rule out potential compensatory regulations of DHFR in angiotensin IIassociated hypertension, where mechanical forces or inflammatory substances may regulate the enzyme differentially. Angiotensin II may also regulate DHFR differently in other vascular cells, such as vascular smooth muscle, whose H 4 B bioavailability, however, is unrelated to endothelial NO • production. Of note, angiotensin II down-regulation of endothelial DHFR was H 2 O 2 -dependent. This observation shares similarity with previous findings that angiotensin II modulates expression of endothelial adhesion molecules by means of H 2 O 2 -dependent mechanisms (29) .
In addition, H 2 O 2 -dependent down-regulation of DHFR mediated angiotensin II induction of H 4 B deficiency and eNOS uncoupling. Angiotensin II stimulation led to a significant reduction in endothelial H 4 B content, which was preventable by removal of H 2 O 2 . It was previously reported that exogenous H 2 O 2 up-regulates GTP-CH I expression (23) , which likely explains a modest increase in total biopterin content observed in the current study. Endogenously produced H 2 O 2 by angiotensin II, however, did not seem to modulate GTP-CH I because angiotensin II had no effect on total biopterin content. These data may suggest that DHFR is much more sensitive to lower endogenous H 2 O 2 compared to GTP-CH I, which was found regulated only in response to exogenous H 2 O 2 . Furthermore, we found that endothelial O 2
•Ϫ production after prolonged angiotensin II (24 h) was completely dependent on uncoupled eNOS and was correctable by scavenging H 2 O 2 or overexpressing DHFR. It is interesting to speculate that this H 2 O 2 downregulation of DHFR may partially underlie eNOS uncoupling in atherosclerotic or hypertension blood vessels.
These data also suggest that, although angiotensin II potently activates vascular NAD(P)H oxidases in endothelial cells and vascular smooth muscle cells within minutes, uncoupled eNOS is the major enzymatic source of ROS within endothelium after prolonged angiotensin II. Indeed, we found that angiotensin II induced an initial burst production of O 2
•Ϫ at 30 min which was abolished by Rac1 inhibitor NSC 23766 but unaffected by L-NAME. This increase in O 2
•Ϫ diminished at 6 h. At 24 h, however, endothelial cells had a second peak in producing O 2
•Ϫ , which was completely attenuated by L-NAME but unaffected by NSC 23766. These data clearly suggest that a rapid and transient activation of endothelial NAD(P)H oxidases precedes H 2 O 2 -dependent eNOS uncoupling. These observations seems consistent with the earlier observation by Mollnau et al. (30) that ROS production in angiotensin II infused rat aorta was markedly reduced by inhibiting eNOS. However, these data are not contradictory to the findings that vascular NAD(P)H oxidases remain the predominant sources for vascular smooth musclederived ROS in response to prolonged angiotensin II (31) . The latter finding seems to also involve up-regulation of NAD(P)H oxidases subunits (32) .
In summary, the present study provided evidence that endothelial DHFR critically regulates endothelial H 4 B and NO
• bioavailability under physiological and pathological conditions. By using angiotensin II as a model system, we found that a rapid and transient activation of endothelial NAD(P)H oxidases precedes H 2 O 2 -dependent down-regulation of DHFR and eNOS uncoupling in the endothelium. This signaling cascade, as illustrated in Fig. 9 , may represent a universal mechanism whereby eNOS uncouples under conditions associated with oxidant stress, such as atherosclerosis, hypertension, and diabetes, for which activation of vascular NAD(P)H oxidases has been documented. Schematic mechanisms underlying angiotensin II uncoupling of eNOS. Angiotensin II induces a rapid and transient activation of endothelial NAD(P)H oxidases (attenuatable by Rac1 inhibitor NSC 23766), leading to an initial burst production of O 2
• Ϫ and formation of H2O2. H2O2 in turn downregulates DHFR to induce H 4B deficiency and eNOS uncoupling. These findings may represent a universal mechanism whereby eNOS dysfunction occurs under conditions associated with oxidant stress.
